Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reaffirmed at Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Financial Group in a research note issued on Friday, September 25th, Digital Look reports. They currently have a GBX 2,025 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 28.16% from the stock’s current price.

A number of other research firms have also weighed in on HIK. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Citigroup boosted their price objective on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Berenberg Bank increased their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 2,085.83.

Hikma Pharmaceuticals Stock Up 0.6%

Shares of Hikma Pharmaceuticals stock traded up GBX 9 during trading hours on Friday, reaching GBX 1,580. The company’s stock had a trading volume of 290,504 shares, compared to its average volume of 4,468,575. The company has a market capitalization of £3.27 billion, a P/E ratio of 8.98, a P/E/G ratio of 2.38 and a beta of 0.66. The stock’s fifty day simple moving average is GBX 1,606.70 and its two-hundred day simple moving average is GBX 1,488.94. Hikma Pharmaceuticals has a one year low of GBX 1,187 and a one year high of GBX 1,865. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98.

Insider Activity

In other news, insider Tobias Hestler bought 7,500 shares of the stock in a transaction dated Monday, August 10th. The stock was bought at an average price of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is currently owned by insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.